CSL partners with Alentis Therapeutics in up to $1.6bn deal to co-develop lixudebart, a claudin-1-targeting antibody for fibrosis indications.
PRIVATEOct 05, 2026
Amount Raised
$1.6 Billion
Round Type
Venture
AllschwilManufacturing
Investors
Csl
Description
Alentis Therapeutics has entered into an exclusive global partnership with Australian biopharmaceutical company CSL for the co-development and co-commercialization of lixudebart, an investigational antibody targeting claudin-1. Under the agreement, CSL will lead a clinical program and assume financial responsibility for development, including the ongoing Phase II RENAL trial, a planned Phase III study in AAV-RPGN, and additional Phase II trials in FSGS and PSC. The deal provides Alentis with up to $1.6 billion in potential payments. Lixudebart represents the lead program from Alentis' proprietary claudin-1 platform, which the Basel-based biotech has developed around a protein involved in cell-cell barriers.
Company Information
Company
Alentis Therapeutics
Location
Allschwil, Basel-Landschaft, Switzerland
About
Alentis Therapeutics is a clinical-stage biotechnology company pioneering first-in-class antibody-drug conjugates (ADCs) and antibodies targeting Claudin-1 (CLDN1) for oncology and multi-organ fibrosis. CLDN1 is a previously unexploited target that plays a key role in the pathology of cancer and fibrotic disease. Alentis is the leading company pioneering CLDN1 ADCs and antibodies to modify and reverse the course of select diseases.
Fundz sees it the moment Alentis Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
AllschwilManufacturing